Table 1.
Baseline Characteristics of the Study Participants
| HIV-Infected PCV Arm (n=131) | HIV-Infected PPV Arm (n=73) | HIV-Infected Overall (n=204) | p-value1 | HIV-Uninfected Arm (n=25) | p-value2 | |
|---|---|---|---|---|---|---|
| Demographics | ||||||
| Age, median (IQR) years | 42 (36 – 47) | 42 (35 – 46) | 42 (36–47) | 0.81 | 37 (29 – 46) | 0.16 |
| Gender, N (%) male | 120 (91.6) | 70 (95.9) | 190 (93.1) | 0.25 | 18 (72.0) | 0.005 |
| Ethnicity, N (%) | 0.98 | 0.01 | ||||
| Caucasian | 71 (54.2) | 40 (54.8) | 111 (54.4) | 21 (84.0) | ||
| African American | 50 (38.2) | 27 (37.0) | 77 (37.7) | 2 (8.0) | ||
| Other | 10 (7.6) | 6 (8.2) | 16 (7.8) | 2 (8.0) | ||
| Clinical History | ||||||
| History of Pneumonia, N (%) | 22 (16.8) | 13 (17.8) | 35 (17.2) | 0.85 | 1 (4.0) | 0.10 |
| Time since last PPV, median (IQR) years | 4.6 (3.7 – 6.1) | 4.7 (3.6 – 5.9) | 4.6 (3.6 – 6.0) | 0.55 | --- | --- |
| HIV History | ||||||
| Time from HIV diagnosis, median (IQR) years | 10.2 (5.0–16.3) | 8.9 (4.4–13.5) | 9.5 (4.8–15.4) | 0.20 | --- | --- |
| CDC Stage, N (%) | 0.46 | --- | --- | |||
| A | 91 (69.5) | 55 (75.3) | 146 (71.6) | |||
| B | 25 (19.1) | 9 (12.3) | 34 (16.7) | |||
| C | 15 (11.5) | 9 (12.3) | 24 (11.8) | |||
| CD4+ T cell count, median (IQR) | 533 (396 – 700) | 513 (388 – 714) | 533 (391 – 701) | 0.85 | --- | --- |
| cells/mm3 CD4+ T cell categories, N (%) | 0.52 | --- | --- | |||
| <200 | 4 (3.1) | 3 (4.1) | 7 (3.4) | |||
| 200–350 | 17 (13.0) | 6 (8.2) | 23 (11.3) | |||
| 351–500 | 35 (26.7) | 26 (35.6) | 61 (29.9) | |||
| 500–750 | 53 (40.5) | 24 (32.9) | 77 (37.7) | |||
| >750 | 22 (16.8) | 14 (19.2) | 36 (17.6) | |||
| HIV RNA, median (IQR) log10 copies/ml | 1.7 (1.7 – 2.2) | 1.7 (1.7 – 3.1) | 1.7 (1.7 – 2.3) | 0.39 | --- | --- |
| HIV RNA <50 copies/ml, N (%) | 91 (69.5) | 47 (64.3) | 138 (68.0) | 0.54 | --- | --- |
| Current HAART, N (%) | 111 (84.7) | 56 (76.7) | 167 (81.9) | 0.15 | --- | --- |
| Baseline Serology Data, Median (IQR) ng/ml | ||||||
| Serotype 4 | 293 (108–793) | 254 (105–580) | 278 (106–726) | 0.50 | 264 (108–595) | 0.47 |
| Serotype 9V | 556 (258–1389) | 425 (237–1269) | 502 (246–1277) | 0.26 | 746 (488–1437) | 0.32 |
| Serotype 14 | 860 (321–5039) | 771 (218–3083) | 817 (315–3733) | 0.31 | 254 (99–564) | <0.001 |
| Serotype 19F | 723 (329–1971) | 480 (239–1154) | 604 (302–1697) | 0.08 | 737 (182–1127) | 0.45 |
1
Comparison of the HIV-infected PCV and PPV arms
2
Comparison of the HIV-infected PCV arm with the HIV-uninfected PCV arm